CNBC’s Jim Cramer on Friday evaluated the stock of Abbott Laboratories, a healthcare company that’s been weighed down by ...

This month, we explore the 125-year-old history of Abbott Laboratories and its most significant ... The company had expanded too, with branches in New York, San Francisco, Seattle and Toronto ...

Since my previous article, shares of Abbott Laboratories have returned 10% versus the 7% gains of the S&P 500 index. The healthcare company's sales and adjusted diluted EPS rose in the third quarter.

Investors happily greeted the latest news from Abbott Laboratories (NYSE: ABT) on Hump Day. After the storied healthcare company unveiled its third-quarter results, those folks traded its stock up ...

Is the company still worth a look if you're a long-term investor? Abbott Laboratories is one of the world's leading medical device makers. It routinely develops and markets newer products ...

Abbott Laboratories showcases robust financial performance with a notable increase in net earnings. Strategic acquisitions and product launches strengthen the company's market presence.

Abbott Laboratories ABT will release its quarterly earnings report on Wednesday, 2024-10-16. Here's a brief overview for investors ahead of the announcement. Analysts anticipate Abbott ...

If a company's history and track record were good enough reasons to buy its shares, it'd be easy to make a case for investing in Abbott Laboratories (NYSE: ABT). Abbott is a longtime leader in the ...